Cullinan Oncology is a biopharmaceutical company. Co. is evaluating its primary candidate, CLN-081, in a trial in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations who have previously received platinum-based chemotherapy. Co.'s two other clinical stage programs include CLN-049, a bispecific T cell-engaging antibody targeting FLT3 and CD3 that is in an ongoing clinical trial for patients with relapsed or refractory acute myeloid leukemia; and CLN-619, a monoclonal antibody that stabilizes a tumor cell surface target, MICA/MICB, to promote an antitumor response via activation of both natural killer cells and certain T cells. We show 9 historical shares outstanding datapoints in our coverage of CGEM's shares outstanding history.
Understanding the changing numbers of CGEM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CGEM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CGEM by allowing them to research CGEM shares outstanding history
as well as any other stock in our coverage universe. |
Free CGEM Email Alerts:
Video: Shares Outstanding Importance
